Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378

Reuters

05-23

Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of an upfront payment in cash and equity under a license agreement with Windward Bio AG for the co-development project SKB378/HBM9378/WIN378. This project involves a novel, recombinant fully human monoclonal antibody designed to potently bind to the TSLP ligand and inhibit the TSLP mediated signaling pathway, relevant in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company recently received regulatory approval for an IND application for SKB378/HBM9378/WIN378 in January 2025 for the treatment of COPD from the National Medical Products Administration in China. A phase 1 clinical trial for moderate-to-severe asthma has been completed, and Windward Bio is preparing for a phase 2 trial. However, the company has cautioned shareholders and potential investors that SKB378/HBM9378/WIN378 may not ultimately be successfully developed and commercialized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537185606"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537185606\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537185606?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537185606","market":"us","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of an upfront payment in cash and equity under a license agreement with Windward Bio AG for the co-development project SKB378/HBM9378/WIN378. This project involves a novel, recombinant fully human monoclonal antibody designed to potently bind to the TSLP ligand and inhibit the TSLP mediated signaling pathway, relevant in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company recently received regulatory approval for an IND application for SKB378/HBM9378/WIN378 in January 2025 for the treatment of COPD from the National Medical Products Administration in China. A phase 1 clinical trial for moderate-to-severe asthma has been completed, and Windward Bio is preparing for a phase 2 trial. However, the company has cautioned shareholders and potential investors that SKB378/HBM9378/WIN378 may not ultimately be successfully developed and commercialized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-23 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of an upfront payment in cash and equity under a license agreement with Windward Bio AG for the co-development project SKB378/HBM9378/WIN378. This project involves a novel, recombinant fully human monoclonal antibody designed to potently bind to the TSLP ligand and inhibit the TSLP mediated signaling pathway, relevant in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company recently received regulatory approval for an IND application for SKB378/HBM9378/WIN378 in January 2025 for the treatment of COPD from the National Medical Products Administration in China. A phase 1 clinical trial for moderate-to-severe asthma has been completed, and Windward Bio is preparing for a phase 2 trial. However, the company has cautioned shareholders and potential investors that SKB378/HBM9378/WIN378 may not ultimately be successfully developed and commercialized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1934453819.USD","symbol_name":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL3gFccW:1","article_id":"2537185606","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537185606","pubTimestamp":1747989604,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","002422":"科伦药业","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK0060":"抗癌","06990":"科伦博泰生物-B","BK0239":"医药制造","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1161":"生物科技","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC"},"translate_title":"四川科伦生物宣布新型哮喘和COPD治疗SKB378/HBM9378/WIN378的2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002422":0.9,"06990":0.9},"content_text":"Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378\n    \n\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of an upfront payment in cash and equity under a license agreement with Windward Bio AG for the co-development project SKB378/HBM9378/WIN378. This project involves a novel, recombinant fully human monoclonal antibody designed to potently bind to the TSLP ligand and inhibit the TSLP mediated signaling pathway, relevant in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company recently received regulatory approval for an IND application for SKB378/HBM9378/WIN378 in January 2025 for the treatment of COPD from the National Medical Products Administration in China. A phase 1 clinical trial for moderate-to-severe asthma has been completed, and Windward Bio is preparing for a phase 2 trial. However, the company has cautioned shareholders and potential investors that SKB378/HBM9378/WIN378 may not ultimately be successfully developed and commercialized.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}